HZHans Rolando Zamora-Obando

Hans Rolando Zamora-Obando

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hans Rolando Zamora-Obando has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Self-organizing maps to aid prognostic and diagnostic biomarker identification in exploratory metabolomics of benign prostatic hyperplasia

    by André Luiz Melo Camelo, André Matos de Oliveira, Hans Rolando Zamora-Obando, Aline Cristina Dias, Thaís de Assis Lopes, Regina Vincenzi Oliveira, João Pedro Simon Farah, Marina Franco Maggi Tavares, Alberto Azoubel Antunes, Ana Valéria Colnaghi Simionato

  • Self-organizing maps to aid prognostic and diagnostic biomarker identification in exploratory metabolomics of benign prostatic hyperplasia

    by André Luiz Melo Camelo, André Matos de Oliveira, Hans Rolando Zamora-Obando, Aline Cristina Dias, Thaís de Assis Lopes, Regina Vincenzi Oliveira, João Pedro Simon Farah, Marina Franco Maggi Tavares, Alberto Azoubel Antunes, Ana Valéria Colnaghi Simionato

    Population aging is increasing rapidly, representing a global trend that has launched many discussions regarding older adult's quality of life. Benign prostatic hyperplasia (BPH) is a commonly found condition among older men, affecting the lower urinary tract and quality of life. BPH diagnosis typically involves clinical evaluations which cannot accurately identify patients who will develop a clinically significant disease in the future. Metabolomics emerges as a promising approach to understand the metabolic pathways associated with BPH, offering potential aid in early diagnosis. To investigate the metabolic profile of BPH patients compared with a control group for diagnosing BPH at different stages. A total of 62 individuals were selected and divided into two groups: 32 BPH (prostate volume > 40 mL) and 30 healthy individuals (prostate volume ≤ 40 mL and normal voiding patterns). Plasma samples were analyzed by LC-HRMS. Data were processed using unsupervised and supervised techniques. Self-organizing maps were further used to aid in the identification of potential biomarkers. Self-organizing maps revealed three distinct groups which expanded upon the existing groups indicated by the medical team. Discriminant analysis models showed good predictive ability and accuracy, providing a classification perspective of patients and expanding diagnostic possibilities for different health states. Integration of chemical data with clinical variables revealed meaningful correlations. Our results also suggest the presence of discriminatory metabolites related to inflammation and oxidation processes, clarifying the metabolic basis of BPH. Self-organizing maps proved their effectiveness in classifying groups of samples from BPH patients, revealing potential biomarkers that went undetected by conventional data analysis methods. This approach underscores metabolomics as a relevant tool in identifying hidden patterns and supporting the development of more robust diagnostic and prognostic models.


  • Open Access

    COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?

    by André Luiz Melo Camelo, Hans Rolando Zamora Obando, Isabela Rocha, Aline Cristina Dias, Alessandra de Sousa Mesquita, Ana Valéria Colnaghi Simionato

    The COVID-19 pandemic has brought about diverse impacts on the global population. Individuals with comorbidities were more susceptible to the severe symptoms caused by the virus. Within the crisis scenario, metabolomics represents a potential area of science capable of providing relevant information for understanding the metabolic pathways associated with the intricate interaction between the viral disease and previous comorbidities. This work aims to provide a comprehensive description of the scientific production pertaining to metabolomics within the specific context of COVID-19 and comorbidities, while highlighting promising areas for exploration by those interested in the subject. In this review, we highlighted the studies of metabolomics that indicated a variety of metabolites associated with comorbidities and COVID-19. Furthermore, we observed that the understanding of the metabolic processes involved between comorbidities and COVID-19 is limited due to the urgent need to report disease outcomes in individuals with comorbidities. The overlap of two or more comorbidities associated with the severity of COVID-19 hinders the comprehension of the significance of each condition. Most identified studies are observational, with a restricted number of patients, due to challenges in sample collection amidst the emergent situation.